HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price trimmed by HC Wainwright from $27.00 to $18.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2029 earnings at ($6.62) EPS.

A number of other equities research analysts have also recently issued reports on ENTA. Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $6.00 on Tuesday. The stock’s fifty day moving average price is $9.40 and its two-hundred day moving average price is $11.57. The company has a market cap of $127.16 million, a price-to-earnings ratio of -1.09 and a beta of 0.49. Enanta Pharmaceuticals has a 52-week low of $5.70 and a 52-week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) EPS. On average, equities analysts predict that Enanta Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after acquiring an additional 85,082 shares during the period. Barclays PLC raised its position in Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 20,478 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the last quarter. Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after buying an additional 246,736 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Enanta Pharmaceuticals in the third quarter worth $360,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.